LLY

Eli Lilly and Company

Healthcare
1064.15 -17.81 -1.65% Market Closed
2026-06-02 • USD

Key Metrics

Market Cap 1002.15B
EV —
Shares Out 941.74M
Revenue (ttm) 72.25B
Net Income 25.28B
Beta —
P/E 37.66
Forward P/E —
EPS (ttm) $28.15
P/S 13.18
P/B 30.51
P/FCF —
P/C —
EV/Sales —
EV/EBITDA —
ROA 23.24%
ROE 102.19%
ROIC —
Gross Margin —
Oper. Margin —
Profit Margin 34.99%
Debt/Eq 1.39
LT Debt/Eq 55.79%
Quick Ratio —
Current Ratio 1.50
Book/sh 34.88
Cash/sh 5.9
Div Yield 0.92%
Div TTM $9.82
Payout Ratio 34.88%
SMA20 3.6%
SMA50 10.74%
SMA200 13.03%
Volume 2,408,537
Avg Volume 3.22M
Rel Volume —
Perf Week -5.56%
Perf Month 9.94%
Perf Quarter 6.04%
Perf Half Y 4.90%
Perf YTD -0.98%
Perf Year 38.95%
Perf 3Y 140.58%
Perf 5Y 426.75%

Factor Lens

Seasonal Performance

Dividends

Per-share amounts adjusted for stock splits.

Last Dividend $3.0000
TTM Yield 0.92%
TTM Amount $9.82
Payout Ratio 34.88%
3-Yr Growth (CAGR) —
5-Yr Growth (CAGR) —

Last 12 Payouts

Period Ex-Date Amount / Share
Q2 2025 ~2025-06-30 $3.0000
Q2 2024 ~2024-06-30 $2.6000
Q2 2023 ~2023-06-30 $2.2600
Q2 2022 ~2022-06-30 $1.9600
Q2 2021 ~2021-06-30 $1.7000
Q3 2020 ~2020-09-30 $0.7400
Q2 2020 ~2020-06-30 $0.7400
Q2 2019 ~2019-06-30 $1.2900
Q2 2018 ~2018-06-30 $0.5625
Q1 2018 ~2018-03-31 $0.5625
Q4 2017 ~2017-12-30 $0.5600
Q3 2017 ~2017-09-30 $0.5200

Financial Trends

Revenue & Net Income

Earnings Per Share

Margins

Cash Flow

Company Overview

Eli Lilly and Company is a leading global pharmaceutical company engaged in the discovery, development, and delivery of pharmaceutical products. The company discovers and develops medicines across multiple therapeutic areas including cardiometabolic health, oncology, immunology, and neuroscience. Key products include Mounjaro and Zepbound (for weight management and diabetes), Trulicity (for type 2 diabetes), Jardiance (for heart disease and type 2 diabetes), Verzenio (for breast cancer), and Taltz (for immunological conditions). The company operates through research and development, manufacturing, and commercialization of pharmaceutical products globally. Lilly also engages in partnerships and acquisitions to expand its pipeline and capabilities, including recent acquisitions in gene therapy and early-stage biotech. The company focuses on innovation, patient access, and sustainability, with manufacturing facilities worldwide and operations in major markets including the United States, Europe, Japan, and China.

Name
Eli Lilly and Company
Industry
Drug Manufacturers - General
CEO
David A. Ricks · Chair, President and Chief Executive Officer
Employees
37,800 as of 2025-12-31
IPO Date
2021-08-13
Phone
(317) 276-2000
Address
Lilly Corporate Center, Indianapolis, IN 46285
Website
lilly.com

Key Executives

Name Title FY Pay
Michael Harrington Senior Vice President —
Jan Lundberg Senior Vice President, Chief Scientific Officer —
Anat Hakim Executive Vice President, General Counsel and Secretary —
Kathleen Fish Senior Vice President, Chief Financial Officer —
David A. Ricks Chair, President and Chief Executive Officer —

Latest News